MDEL Phase II Amendments 2026: What Medical Device Importers and Distributors Must Do Before December 14

On December 14, 2026, the most significant change to Canada's medical device establishment licensing framework in years takes effect. The Phase II amendments to the Medical Devices Regulations, published as SOR/2026-110 in the Canada Gazette, Part II on June 17, 2026, reshape who needs a medical device establishment licence (MDEL), what every licence holder must keep on file, and how Health Canada will trace devices through the supply chain. Some companies will be able to drop a licence they no longer need. Others will face a new annual obligation to disclose every supplier and to prove, in writing, that their quality procedures actually exist.

This guide explains exactly what is changing, who is affected, and the concrete steps importers, distributors, and Class I manufacturers should take now to be ready before the in-force date.

Executive summary

What is changing? Health Canada has finalized the second phase of its work to modernize medical device establishment licensing. Three core changes take effect on December 14, 2026: a risk-based exemption that removes the MDEL requirement for many foreign distributors, a mandatory supplier list that every MDEL applicant and holder must submit and keep current, and explicit obligations to establish, implement, and maintain documented procedures in place of the old attestation model.

Why does it matter? The amendments tighten supply-chain transparency and shift the burden of proof during inspections. Attesting that procedures exist is no longer enough. Health Canada has stated that inspectors repeatedly found documented procedures that were missing, incomplete, or out of date despite signed attestations, and the new rules close that gap.

What should companies do? Map your supply chain and build a complete, accurate supplier list. Confirm whether you, or your foreign partners, still need an MDEL. Review and update your documented procedures for distribution records, complaints, recalls, incident reporting, and corrective action so they hold up under inspection. Build the supplier list into your annual licence review, which is due before April 1 each year.

Background: from Phase I to Phase II

Health Canada committed to modernizing the MDEL framework in 2018 and 2019, but the COVID-19 pandemic delayed the work. Phase I was published in the Canada Gazette, Part II on June 17, 2024, and came into force on December 14, 2024. That first package (SOR/2024-136) strengthened how recalls are conducted and gave the Minister new powers to impose terms and conditions on an MDEL.

Phase II builds on that foundation. It was pre-published in the Canada Gazette, Part I on November 8, 2025, followed by a public comment period. Health Canada received 38 comments from 9 respondents, which it describes as generally supportive, and considered that feedback before finalizing the regulations. The final amendments were registered on June 4, 2026, published on June 17, 2026, and come into force on December 14, 2026, which is 180 days after publication.

The stated goals are to reduce burden, promote innovation, enhance competitiveness, and align Canada with international regulation, all without compromising the health and safety of people in Canada. This matters because roughly 70% of medical devices used in Canada are imported, with about 42.6% of those coming from the United States. A licensing framework that cannot see into the import supply chain is a framework with a blind spot, and Phase II is designed to remove it.

The three core changes at a glance

Change 1: A risk-based approach to licensing foreign distributors

What is it? Under the current rules, any person who imports a medical device must verify that the person they import from holds an MDEL, and foreign distributors selling into Canada need their own MDEL. Phase II adds a new exemption. A Canadian company that imports a device from someone other than the manufacturer (that is, from a distributor) is no longer required to confirm that distributor holds an MDEL, as long as the Canadian importer itself holds a valid MDEL. The practical effect is that foreign distributors who sell only through a licensed Canadian importer no longer need to hold an MDEL of their own.

Why does it matter? This is the burden-reduction headline of the package. Health Canada estimates that foreign distributors will save roughly $333,000 per year in MDEL fees once the change takes effect. For Canadian importers, it removes the work of verifying a foreign distributor's licence status and of helping overseas partners apply for and maintain a licence they did not really need.

Where the exemption stops. The relief is genuinely risk-based, not blanket. Two situations still require a licence. First, retailers and health care facilities, which are themselves exempt from holding an MDEL, must still ensure that the person they import directly from holds one. Second, a foreign distributor that sells directly to a Canadian retailer or health care facility, rather than only through a licensed importer, still needs an MDEL. In short, the exemption applies when a licensed Canadian importer sits between the foreign distributor and the Canadian market, because that importer carries the regulatory accountability.

What should companies do? Confirm exactly how each device enters Canada and who imports it. If you are a Canadian importer, identify which of your foreign suppliers can stop maintaining an MDEL, and document the change so your records stay consistent. If you are a foreign distributor, do not cancel a licence until you have verified that every Canadian sales channel runs through a licensed importer. A single direct sale to a retailer or hospital can keep you in licence-required territory.

Change 2: The mandatory supplier list

What is it? Phase II adds two new requirements to section 45 of the Medical Devices Regulations. Every MDEL applicant and holder must provide the name and address of any person, other than the manufacturer, who sells them a medical device for the purpose of importation or distribution, and must identify the classes of devices being imported or distributed from each of those suppliers. Health Canada defines a supplier broadly as any person, other than the manufacturer, who sells a device to an MDEL holder. That includes Canadian importers, domestic distributors selling within Canada, and foreign distributors selling into Canada.

Why does it matter? Supplier visibility is the trade-off for the lighter licensing touch on foreign distributors. By collecting supplier information, Health Canada can identify which licence holders may be importing or selling non-compliant devices and can trace a problem product through the supply chain when a safety risk arises. The department has said this supports more targeted compliance action and faster, better-scoped recalls, because it can tell a company whether a defect traces back to a single supplier or several.

How and when it must be provided. New applicants supply the full list with their MDEL application. Existing holders provide and update the information at the annual licence review, which under the amended subsection 46.1(1) must be submitted before April 1 of each year, together with any updates to the information. Health Canada treats supplier information as confidential business information under the Food and Drugs Act and stores it as Protected B within its internal database, so the list is not published.

The transition trap. There is no extended grace period. Industry asked for twelve months and Health Canada held firm at six, noting that about one third of importers and distributors already provide supplier information voluntarily. There is also a transitional rule with teeth: if your MDEL application is still in the queue when the amendments come into force and no decision has been made, Health Canada will not issue the licence until you provide the new supplier information in the required form. Companies with applications pending into late 2026 should prepare the supplier list now rather than wait for a request.

Change 3: Documented procedures, made explicit

What is it? The current rules ask MDEL applicants to attest that they have documented procedures for activities such as distribution records, complaint handling, and recalls. Phase II removes those attestations and replaces them with explicit, standalone obligations. Manufacturers, importers, and distributors must each establish, implement, and maintain documented procedures for the relevant safety-management activities. The amendments spell this out across several provisions:

• Distribution records under subsection 52(3): procedures for maintaining the records that let you withdraw a device from the market quickly.
• Complaint handling under section 58: procedures that enable the required complaint-handling actions.
• Handling, storage, delivery, installation, servicing, and corrective action under the new section 58.1, which applies to Class II, III, and IV devices.
• Mandatory problem (incident) reporting under subsections 59(3) and (4), covering preliminary and final reports.
• Provision of information about a serious risk of injury under subsection 61.2(4), which applies to medical device licence holders and importers of Class II, III, and IV devices.

Why does it matter? Health Canada was explicit about the driver. During inspections, it observed that documented procedures for safety-management activities were often missing or incomplete, that there were gaps in how procedures were documented and implemented, and that procedures were sometimes out of date, even where an attestation had been signed. By making the obligation a direct regulatory requirement rather than a box-tick at application, the rule changes what an inspector can cite. A missing or stale procedure is now a clear regulatory gap.

A clarification, not new burden, for most. Health Canada states that these requirements are not new and do not impose additional burden. The requirements remain outcome-based, which means the department does not prescribe the format or content of a procedure. Class II, III, and IV manufacturers are already expected to maintain such procedures as part of their quality management system certification under the Medical Device Single Audit Program (MDSAP), which satisfies ISO 13485:2016. Two points are worth flagging. The new section 58.1 (handling, storage, delivery, installation, servicing, and corrective action) does not apply to Class I devices, while the incident-reporting procedure requirements do reach Class I manufacturers and importers. Health Canada has also repealed the old requirement to list the medical specialties for which a device is imported or distributed, because that information served no regulatory use.

What it means for your inspection readiness

The combined message of Phase II is that paperwork must now match practice. An attestation could be signed in good faith and still mask a thin or outdated procedure. After December 14, 2026, the procedure itself is the requirement, and an inspector who finds it missing, incomplete, or unimplemented has a direct basis to act. Health Canada has confirmed that compliance and enforcement will follow a risk-based approach aligned with its existing compliance and enforcement policy (POL-0001), and that the MDEL service standard remains 120 days, subject to the Pause-the-clock policy used to solicit missing information.

It is worth being clear about what has not changed. The importer remains the party responsible for conducting a recall under the Medical Devices Regulations. Removing the licensing requirement for foreign distributors does not move that responsibility, and it does not reduce Health Canada's ability to oversee recalls. If anything, the supplier list strengthens that oversight.

Who is affected, and what to do

Different parties in the supply chain are affected in different ways. The table below summarizes the practical impact.

What it costs

Health Canada estimates that about 2,300 importers and distributors will be required to submit supplier information. Of those, roughly 800 organizations already do so voluntarily, leaving about 1,500 that will need to start in the first year. After the first year, about 240 organizations apply for a new MDEL annually and will file a full list, while around 1,260 will simply update their information at the annual review. A typical initial list runs to about 11 suppliers.

The monetized cost of the supplier-list requirement is about $1.8 million in present value over ten years across industry and government, which Health Canada characterizes as modest relative to the transparency and burden-reduction benefits. About half of MDEL holders identify as small businesses, and the department estimates small businesses will carry roughly $840,000 of the industry cost over that period, partly offset by a larger pool of available distributors once foreign-distributor licensing is relaxed.

Compliance checklist: be ready before December 14, 2026

Use this checklist to structure your readiness work over the coming months.

• Map your supply chain. List every person, other than the manufacturer, who sells you a device for import or distribution, including Canadian importers, domestic distributors, and foreign distributors.
• Build the supplier list. Capture each supplier's name, address, and the device classes (I, II, III, IV) supplied. Decide where this list will live so it can be updated and produced on demand.
• Confirm your licensing position. Determine whether any foreign distributor partners can drop their MDEL, and whether you, as an importer, still need to verify anyone's licence.
• Check direct-to-market channels. Identify any foreign distributor that sells directly to a Canadian retailer or health care facility, because those channels still require an MDEL.
• Audit your documented procedures. Review procedures for distribution records, complaint handling, recalls, mandatory problem reporting, corrective action, and the provision of serious-risk information against sections 52, 58, 58.1, 59, and 61.2.
• Close procedure gaps. Where a procedure is missing, incomplete, or out of date, rewrite it so it reflects actual practice and current regulatory references.
• Handle pending applications. If an MDEL application will be in the queue near December 2026, prepare the supplier information now so a licence is not held back.
• Build it into the annual licence review. Add supplier-list verification to your pre-April-1 annual review routine so updates are never missed.
• Train your team. Make sure quality and regulatory staff understand that signed attestations no longer substitute for living, implemented procedures.

Build your supplier list: what to capture

The regulation requires a supplier's name, address, and the device classes supplied, but a list that only meets the minimum is hard to maintain and harder to defend at the annual review. Capture a few extra fields so the same list also tells you who can drop a licence and who cannot. The structure below is the one we recommend, and it matches the free MFLRC supplier-list template.

Documented-procedure gap checklist

Work through each required procedure and ask three questions: does it exist, is it current, and is it actually implemented with evidence on file. Any no is a gap to close before December 14, 2026. This is the same structure as the free MFLRC gap checklist.

Your December 14, 2026 readiness roadmap

A deadline without a sequence is just pressure. The roadmap below breaks the work into monthly milestones so nothing is left to the last week. Assign an owner to each step. The downloadable MFLRC roadmap adds a completion tracker.

To put this into practice, MFLRC has prepared three free, brand-ready tools that mirror the sections above: an MDEL supplier-list template, a documented-procedure gap checklist, and a one-page December 14 readiness roadmap. Contact MFLRC to request them or to book a readiness assessment.

Common mistakes to avoid

Treating the supplier list as a one-time task. The list is not filed once and forgotten. It must be reviewed and updated every year at the annual licence review, before April 1. Companies that fail to build this into an annual routine risk filing stale information.

Cancelling a foreign MDEL too early. The exemption only applies where a licensed Canadian importer stands between the foreign distributor and the market. Cancelling a licence while a direct-to-retailer or direct-to-hospital channel still exists creates a compliance gap.

Assuming attestation-era procedures will pass. Procedures that were good enough to support an attestation may be incomplete or outdated. After December 14, 2026, the procedure itself is inspected, not the attestation about it.

Forgetting Class I obligations. Class I manufacturers and importers are not exempt from the incident-reporting procedure requirements, even though section 58.1 does not apply to them. Class I manufacturers also hold MDELs and must file supplier information.

Waiting on a pending application. If your application is still being processed when the rules take effect, the licence will not be issued until supplier information is provided. Preparing it late can delay market access.

Frequently asked questions

When do the MDEL Phase II amendments come into force?

The amendments (SOR/2026-110) come into force on December 14, 2026, which is 180 days after publication in the Canada Gazette, Part II on June 17, 2026.

Do foreign distributors still need an MDEL?

Not always. A foreign distributor that sells only through a Canadian importer holding an MDEL no longer needs its own MDEL. A foreign distributor that sells directly to a Canadian retailer or health care facility still needs one.

What information goes on the supplier list?

For each person other than the manufacturer who sells you a device for import or distribution, you must provide their name and address and identify the classes of devices supplied. Health Canada treats this information as confidential.

When is the supplier list due?

New applicants submit it with their MDEL application. Existing holders submit and update it at the annual licence review, which is due before April 1 each year.

What changed with documented procedures?

The old model relied on attestations that procedures existed. Phase II replaces those attestations with explicit requirements to establish, implement, and maintain documented procedures for distribution records, complaint handling, corrective action, incident reporting, and the provision of serious-risk information.

Are the documented-procedure requirements new obligations?

Health Canada describes them as a clarification rather than a new burden. The requirements are outcome-based, and Class II to IV manufacturers already maintain such procedures under their MDSAP quality management system certification.

Does removing foreign-distributor licensing change who handles a recall?

No. The importer remains responsible for conducting a recall under the Medical Devices Regulations, and Health Canada's oversight of recalls is unchanged.

How MFLRC can help

MFLRC helps medical device importers, distributors, and Class I manufacturers turn the Phase II amendments into a clear, defensible plan before the December 14, 2026 deadline. Our work in medical devices and regulatory affairs, licensing, and import/export covers the full lifecycle of an MDEL, from initial application through annual licence review.

We support clients with:

• MDEL applications and licensing strategy, including a clear read on whether you or your foreign partners still need a licence under the new risk-based approach.
• Supplier-list development and supplier qualification, so your list is complete, accurate, and ready for the annual review.
• Documented-procedure and SOP development for distribution records, complaint handling, recalls, incident reporting, and corrective action that match actual practice.
• Quality management system builds aligned to ISO 13485 and MDSAP expectations through our quality assurance and control services.
• Inspection-readiness and gap assessments through our audit services, so missing or outdated procedures are found and fixed before an inspector finds them.

Need help getting ready for December 14? Book a consultation for an MDEL readiness assessment, including a documented-procedure and supplier-list gap review tailored to your devices and supply chain.

Conclusion

The Phase II amendments are a genuine two-way trade. Health Canada lightens the licensing load on foreign distributors who work through licensed Canadian importers, and in exchange it gains a clear, annually updated view of who supplies the Canadian market and firmer ground to inspect the procedures that keep devices safe. For most established companies the documented-procedure changes confirm what good practice already requires, but the shift from attestation to direct obligation raises the stakes if procedures have quietly drifted out of date. The supplier list, meanwhile, is a new annual discipline that rewards companies who build it into their licence-review routine and penalizes those who treat it as a one-time form. The deadline is fixed and there is no grace period beyond December 14, 2026. The companies that map their supply chains, confirm their licensing positions, and tighten their procedures now will cross that date without disruption.

Sources and references

Health Canada, Phase 2 of our work to modernize medical device establishment licensing, MDCP Bulletin, June 17, 2026.

Government of Canada, Canada Gazette, Part II: Regulations Amending the Medical Devices Regulations (Establishment Licences), SOR/2026-110, June 17, 2026.

Government of Canada, Canada Gazette, Part I: Regulations Amending the Medical Devices Regulations (Establishment Licences), November 8, 2025.

Health Canada, Guidance on medical device establishment licensing (GUI-0016).

Justice Canada, Medical Devices Regulations (SOR/98-282).